호르몬 수용체 약양성 유방암과 삼중음성 유방암의 치료 예후
Treatment Outcomes of Weakly Positive Hormone Receptor Breast Cancer and Triple-Negative Breast Cancer
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: In breast cancer, response to endocrine therapy depends on estrogen receptor and progesterone receptor status. However, poor prognosis is conferred on patients with hormone receptor (HR)-positive breast cancer. We aimed to examine weakly positive HR breast cancer by comparing weakly positive HR to strongly positive HR and negative HR breast cancer. Methods: We examined the clinical and biological features of 1,496 women with breast cancer, and these patients were categorized according to HR status as weakly positive, strongly positive, and negative HR breast cancer. Results: In this study, among 1,496 patients with breast cancer, negative HR breast cancer was found in 374, weakly positive HR breast cancer in 90 and strongly positive HR breast cancer in 1,032 patients. Our multivariate analysis showed that there were differences in T stage, tumor–node–metastasis stage, vascular invasion, histologic grade and type, and Ki-67 index. Patients with weakly positive HR breast cancer had an increased risk of death and recurrence compared with those with strongly positive HR breast cancer and had similar prognosis as patients with negative HR breast cancer. Conclusion: Patients with weakly positive HR breast cancer received endocrine therapy because they were regarded as having positive HR breast cancer. However, their prognosis of overall survival and relapse-free survival was similar to that in patients with negative HR breast cancer. Therefore, we need to closely observe and consider active treatment for patients with weakly positive breast cancer.
Abstract
Purpose: In breast cancer, response to endocrine therapy depends on estrogen receptor and progesterone receptor status. However, poor prognosis is conferred on patients with hormone receptor (HR)-positive breast cancer. We aimed to examine weakly positive HR breast cancer by comparing weakly positive HR to strongly positive HR and negative HR breast cancer. Methods: We examined the clinical and biological features of 1,496 women with breast cancer, and these patients were categorized according to HR status as weakly positive, strongly positive, and negative HR breast cancer. Results: In this study, among 1,496 patients with breast cancer, negative HR breast cancer was found in 374, weakly positive HR breast cancer in 90 and strongly positive HR breast cancer in 1,032 patients. Our multivariate analysis showed that there were differences in T stage, tumor–node–metastasis stage, vascular invasion, histologic grade and type, and Ki-67 index. Patients with weakly positive HR breast cancer had an increased risk of death and recurrence compared with those with strongly positive HR breast cancer and had similar prognosis as patients with negative HR breast cancer. Conclusion: Patients with weakly positive HR breast cancer received endocrine therapy because they were regarded as having positive HR breast cancer. However, their prognosis of overall survival and relapse-free survival was similar to that in patients with negative HR breast cancer. Therefore, we need to closely observe and consider active treatment for patients with weakly positive breast cancer.
참고문헌 (22)
- 김지선, "The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database", Journal of Breast Cancer, 18(2), pp.103~111 (2015), 한국유방암학회
- Allred DC, "Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance", Arch Surg, 125, pp.107~113 (1990)
- Arpino G, "Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance", J Natl Cancer Inst, 97, pp.1254~1261 (2005)
- Bae SY, "Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer", BMC Cancer, 15, pp.138~ (2015)
- Iwamoto T, "Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry", J Clin Oncol, 30, pp.729~734 (2012)
- Khoshnoud MR, "Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen", Breast Cancer Res Treat, 126, pp.421~430 (2011)
- Nadji M, "Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers", Am J Clin Pathol, 123, pp.21~27 (2005)
- Clark GM, "Prognostic and predictive factors for breast cancer", Breast Cancer, 2, pp.79~89 (1995)
- Sheffield BS, "Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor", Breast Cancer Res Treat, 155, pp.483~490 (2016)
- Qureshi A, "Allred scoring for ER reporting and it’s impact in clearly distinguishing ER negative from ER positive breast cancers", J Pak Med Assoc, 60, pp.350~353 (2010)
- Fan Y, "Prognostic significance of single progesterone receptor positivity: a comparison study of estrogen receptor negative", progesterone receptor positive, Medicine (Baltimore), pp.2015, 94[DOI]
- Hawkins RA, "Prognostic significance of oestrogen and progestogen receptor activities in breast cancer", Br J Surg, 74, pp.1009~1013 (1987)
- Robertson JF, "Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer", Int J Biol Markers, 11, pp.29~35 (1996)
- Hu Z, "The molecular portraits of breast tumors are conserved across microarray platforms", BMC Genomics, 7, pp.96~ (2006)
- Sorlie T, "Repeated observation of breast tumor subtypes in independent gene expression data sets", Proc Natl Acad Sci U S A, 100, pp.8418~8423 (2003)
- Cheang MC, "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer", J Natl Cancer Inst, 101, pp.736~750 (2009)
- Vallejos CS, "Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database", Clin Breast Cancer, 10, pp.294~300 (2010)
- Foulkes WD, "Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer", J Natl Cancer Inst, 95, pp.1482~1485 (2003)
- Gerratana L, "Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype", Cancer Treat Rev, 68, pp.102~110 (2018)
- Gucalp A, "Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer", Clin Cancer Res, 19, pp.5505~5512 (2013)
- Morikawa A, "Palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer", Clin Cancer Res, 21, pp.3591~3596 (2015)
- Turner NC, "Palbociclib in hormone-receptor-positive advanced breast cancer", N Engl J Med, 373, pp.209~219 (2015)